Publication details
Ustekinumab - nová možnost terapie psoriázy
| Title in English | Ustekinumab - a new option of psoriasis therapy |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Praktické lékárenství |
| MU Faculty or unit | |
| Citation | |
| Field | Dermatovenerology |
| Keywords | ustekinumab; p40 blockers; psoriasis; biologic treatment |
| Description | Psoriasis is a chronic inflammatory disease that can be treated with biologics. Ustekinumab is a new group of biologics called p40 blockers. Ustekinumab is a fully human monoclonal antibody that binds to the protein subunit p40 of the interleukins IL-12 and IL-23. This results in the blockade of the activation of T-lymphocytes that prevents their differentiation to Th1 and Th17 cells, with subsequent blocking of secretion of proinflammatory mediators (TNF-alfa, IFN-gamma, IL-17, IL-22). Ustekinumab is administered in subcutaneous injections, 45 mg for dose (or 90 mg for dose in patients heavier than 100 kg), at weeks 0 and 4 and than once every 12 weeks. |